DL-AP5

Product Description

DL-AP5 is a racemic mixture of the D- and L-isomers of AP5, a selective NMDA receptor antagonist that competes with glutamate binding and is commonly used to inhibit NMDA-dependent synaptic plasticity. D-AP5 (Cat. No. 0106) is the more active isomer and displays approximately 52-fold higher potency than the L-isomer, L-AP5 (Cat. No. 0107). In vitro D-AP5 reduces NMDA-induced depolarization of cortical neurons, with no effect on the response to L-Quisqualic acid (Cat. No. 0188) or Kainic acid (Cat. No. 0222). Following spinal injection of D-AP5, NMDA-response is rapidly reduced, with no effect seen on spontaneously active neurons.

D-isomer, L-isomer and sodium salt also available.

Solubility

Preparing Stock Solutions for DL-AP5

The following data is based on the product molecular weight 197.13

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	5.07 mL	25.36 mL	50.73 mL
5 mM	1.01 mL	5.07 mL	10.15 mL
10 mM	0.51 mL	2.54 mL	5.07 mL
50 mM	0.10 mL	0.51 mL	1.01 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Evans The effect of a series of ω-phosphonic-α-carboxylic amino acids on electrically evoked and amino acid induced responses in isolated spinal cord preparations. Br.J.Pharmacol. 1982 PMID: 7042024
• Davies and Watkins Actions of D and L forms of 2-amino-5-phosphonovalerate and 2-amino-4-phosphonobutyrate in the cat spinal cord. Brain Res. 1982 PMID: 6145492